Theravance Biopharma
Theravance Biopharma develops and commercializes small molecule medicines for various therapeutic areas.
Theravance Biopharma develops and commercializes small molecule medicines for various therapeutic areas.
Theravance Biopharma, founded with a mission to transform the treatment of specialty respiratory and neurologic diseases, focuses on the discovery, development, and commercialization of small molecule medicines. The company's vision centers on creating "Medicines that Make a Difference" in patients' and caregivers' lives. Their product pipeline includes treatments for respiratory disease, bacterial infections, and central nervous system disorders, addressing significant patient needs in these therapeutic areas.
Notable affiliates of Theravance Biopharma include a team of experienced scientists and industry professionals dedicated to innovative drug development. The company has attracted substantial investment from leading healthcare investors, contributing to its robust research and development capabilities. Key achievements include the successful advancement of multiple drug candidates through clinical trials, significantly impacting patient care in their target markets. Theravance Biopharma continues to be a pivotal player in the biopharmaceutical industry, driving forward advancements in specialty medicine.
Companies similar to Theravance Biopharma include Therabron Therapeutics, Enanta Pharmaceuticals, MediciNova and Theron Pharmaceuticals.
Theravance Biopharma was founded in 1996.
Theravance Biopharma's headquarters is located in South San Francisco, CA, US.
Theravance Biopharma's most recent funding round was for $100.5M (USD) in June 2021.
As of Jun 25, 2021, Theravance Biopharma has disclosed funding of $663.2M (USD). Undisclosed round amounts are excluded.
Theravance Biopharma has 111 employees as of Feb 6, 2024.
Theron Pharmaceuticals
